Venatorx Pharmaceuticals

Working to improve health outcomes for patients w/ MDR bacterial infections + hard-to-treat viral infections #antibiotics #antivirals #PASTEURact

[Venatorx Pharmaceuticals @VenatorxPharma]

☑ Cefepime-taniborbactam met the primary noninferiority efficacy endpoint and demonstrated statistical superiority to meropenem ☑ Cefepime-taniborbactam was well-tolerated with similar safety profile to meropenem ☑ NDA submission planned Q4'22 https://t.co/36fPprUY7j

[Venatorx Pharmaceuticals @VenatorxPharma]

@Venatorx, @MelintaTx and Menarini Group are thrilled to announce positive Phase 3 Cefepime-Taniborbactamin study results for cUTI in the New England Journal of Medicine (@NEJM) https://t.co/DzW0HiJbOw #antibioticresistance, #antibiotic, #AMR, #superbug

[Venatorx Pharmaceuticals @VenatorxPharma]

Venatorx selects Menarini Group to commercialize Cefepime-Taniborbactamin in 96 countries in Europe, Latin America, Middle East, Turkey, N Africa and CIS. https://t.co/b6qMCoOTXo #antibioticresistance, #antibiotic, #AMR, #superbug

[Venatorx Pharmaceuticals @VenatorxPharma]

We're elated to announce a licensing agreement with @Melinta Therapeutics to commercialize Cefepime-Taniborbactam for cUTI and HABP/VABP in the US https://t.co/X23jSzoKZo #antibioticresistance, #antibiotic, #AMR, #superbug

[Venatorx Pharmaceuticals @VenatorxPharma]

#IDweek2023: cefepime-taniborbactam, an investigational antibacterial agent, demonstrated higher in vitro activity vs antibiotics against clinically significant gram-negative bacteria isolated from #cancer patients at @MDAnderson https://t.co/2eoEq2uP1Q #cancer #StandUptoCancer

[Venatorx Pharmaceuticals @VenatorxPharma]

Venatorx announces its 3rd partnership with @BARDA to support its oral antimicrobial candidate through a Phase 3 clinical trial. If @US_FDA-approved, this product could reduce hospitalization time for patients and combat AMR infections. https://t.co/ofefNqgtWz

[Venatorx Pharmaceuticals @VenatorxPharma]

We are excited to offer seven presentations on our novel antibiotics cefepime-taniborbactam and ceftibuten-ledaborbactam at @IDWeekmtg 2023, October 11-15 in Boston. Read more: https://t.co/Z7RYbYlGBy #antibioticresistance, #antibiotic, #AMR, #superbug, #stopsuperbugs,

[Venatorx Pharmaceuticals @VenatorxPharma]

We are thrilled to be featured in @andyextance's @ChemistryWorld article on innovation in drug development for antibiotic resistance. Read: https://t.co/mtFSdksjqP #antibioticresistance, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

[BioWorld @BioWorld]

FDA accepts @VenatorxPharma NDA for cUTI antibiotic; PDUFA early 2024 #biotech #pharma https://t.co/rS0GzqK0fz

[Venatorx Pharmaceuticals @VenatorxPharma]

We are excited to announce #FDA acceptance and priority review of our #NDA for cefepime-taniborbactam to treat #cUTIs, including Pyelonephritis, in adults. The FDA has assigned a #PDUFA date of February 22, 2024. https://t.co/jWhp7SSS56 #AMR, #superbug #antibioticresistance

[Venatorx Pharmaceuticals @VenatorxPharma]

News: 2 recent publications show metallo-beta-lactamases(MBLs) increasing in US CRE isolates. CEO Chris Burns: "...it is essential that next generation antibiotics combat the evolving multi-drug resistant gram- infections, including #MBLs." https://t.co/Mnkx1zsq8Y #AMR, #superbug

[Venatorx Pharmaceuticals @VenatorxPharma]

Join us in welcoming our new Chairman of the Board, Tom Heyman. Tom brings a strong track record of success as an industry leader and board member, and we look forward to his expertise and guidance as we continue to advance our anti-infectives pipeline. https://t.co/Dq0gFDFkVM

[Working to Fight AMR @WeFightAMR]

Antimicrobial resistance or #AMR is a public health crisis. Globally, antibiotic-resistant infections killed 1.2 million people and contributed to nearly 5 million deaths in 2019. Learn more about the fight to stop #superbugs:
https://t.co/vy2hwQsPxU

[LabNotes 🔬📝 @LabNotesPhilly]

In this week's #LabNotes, @keystone_us adds 200K SF of #lab space to The Curtis, @LSGPA partners with #ArgoPond to spur PA investments, @BioBuzzMaryland lists noteworthy firms including @GaleraTx, @VenatorxPharma, & @SparingVision, and more!

Read here 📥: https://t.co/7vQWw3uobO

[Venatorx Pharmaceuticals @VenatorxPharma]

Thank you! We look forward to our continued partnership in advancing these important medicines #antibioticresistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

GARDP congratulates @VenatorxPharma on its @BARDA Project BioShield contract for the development and procurement of cefepime-taniborbactam to treat bacterial infections in health emergencies. We are collaborating with Venatorx on the development & access to this treatment.

[Venatorx Pharmaceuticals @VenatorxPharma]

We looking forward to our continued partnership in advancing these important medicines. #antibioticresistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

[BARDA @BARDA]

#ICYMI: Last month, we awarded a Project BioShield contract to @VenatorxPharma to develop & potentially procure a new antibiotic to treat #AMR infections during public health emergencies: https://t.co/oX9Q3kXZy0 #WAAW22

[Venatorx Pharmaceuticals @VenatorxPharma]

We are happy to be a part of this vital effort. #antibioticresistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund

[Vivli @VivliCenter]

This June Vivli launched the AMR Register. We work with our members to address the critical need for high-quality, openly accessible AMR surveillance data: https://t.co/asWPkb0l6M #WAAW2022 @pfizer @GSK@JNJNews @Merck @ParatekPharma @shionogi_hc @VenatorxPharma @rebeccali2006

[Venatorx Pharmaceuticals @VenatorxPharma]

Spread the word: it's World Antimicrobial Awareness Week. We support Vivli's AMR Register for #AMR surveillance datasets to drive science & understanding. https://t.co/Mu25ZxJXVz #WAAW2022 #AntibioticResistance #AWG_news #superbug #stopsuperbugs #saveantibiotics #AMRActionFund

[Venatorx Pharmaceuticals @VenatorxPharma]

It also noted this trend is worrisome since there are limited therapeutic options against MBL producers and more treatment options covering these and other resistant isolates are needed. 3/3

[Venatorx Pharmaceuticals @VenatorxPharma]

These data showed that ~20% of CRE are not carbapenemase producers and among CRE with carbapenemases, ~13% were metallo-beta lactases (MBL). 2/3

[Venatorx Pharmaceuticals @VenatorxPharma]

At @IDWeek2022, JMI’s poster #P664 announced US susceptibility results for carbapenem resistant Enterobacterales (CRE) in 2021. #antibiotic resistance, #AWG_news, #antibiotic, #AMR, #superbug, #stopsuperbugs, #saveantibiotics, #AMRActionFund 1/3